



(51) International Patent Classification:

A61K 39/00 (2006.01) A61P 35/00 (2006.01)
C07K 16/24 (2006.01)

(21) International Application Number:

PCT/US2022/071382

(22) International Filing Date:

28 March 2022 (28.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/167,105 28 March 2021 (28.03.2021) US
63/236,454 24 August 2021 (24.08.2021) US

(71) Applicant: IMMUNOME, INC. [US/US]; 665 Stockton Drive, Suite 300, Exton, Pennsylvania 19341 (US).

(72) Inventors: ROBINSON, Matthew K.; c/o Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, Pennsylvania 19341 (US). LUNDGREN, Karen; c/o Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, Pennsylvania 19341 (US). HARMAN, Ben; c/o Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, Pennsylvania 19341 (US). NIKITIN, Pavel A.; c/o Immunome, Inc., 665 Stockton

Drive, Suite 300, Exton, Pennsylvania 19341 (US). SHEN, Fang; c/o Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, Pennsylvania 19341 (US).

(74) Agent: POON, Meghan et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: IL-38-SPECIFIC ANTIBODIES




FIG. 2

(57) Abstract: This invention relates to antibodies specific for human interleukin-38 (IL-38), including isolated antibodies, or antigen-binding fragments thereof. The antibodies, or antigen-binding fragments thereof, described here partially or fully block, inhibit, or neutralize a biological activity of IL 38. Methods described here relate to inhibiting tumor growth or metastasis in an individual afflicted by tumor growth and/or metastasis.

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*